HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sandra Rebouissou Selected Research

Liver Cell Adenoma (Hepatocellular Adenoma)

8/2020Sigma 1 Receptor is Overexpressed in Hepatocellular Adenoma: Involvement of ERα and HNF1α.
1/2020Recurrent chromosomal rearrangements of ROS1, FRK and IL6 activating JAK/STAT pathway in inflammatory hepatocellular adenomas.
1/2018Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas.
1/2017Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation.
2/2013Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I.
10/2011HNF1α inhibition triggers epithelial-mesenchymal transition in human liver cancer cell lines.
2/2010Loss of hepatocyte nuclear factor 1alpha function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorigenesis.
1/2009Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours.
9/2007Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry.
5/2007Genotype phenotype classification of hepatocellular adenoma.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Sandra Rebouissou Research Topics

Disease

26Neoplasms (Cancer)
01/2021 - 08/2004
13Hepatocellular Carcinoma (Hepatoma)
05/2022 - 03/2006
13Liver Cell Adenoma (Hepatocellular Adenoma)
08/2020 - 09/2004
6Liver Neoplasms (Liver Cancer)
10/2021 - 08/2017
6Carcinogenesis
01/2019 - 03/2005
3Urinary Bladder Neoplasms (Bladder Cancer)
01/2019 - 11/2014
3Adenoma (Adenomas)
12/2016 - 03/2006
3Focal Nodular Hyperplasia
07/2008 - 05/2007
2Hypersensitivity (Allergy)
01/2019 - 02/2010
2Hemorrhage
01/2018 - 01/2017
2Carcinoma (Carcinomatosis)
07/2012 - 03/2006
1Neoplasm Metastasis (Metastasis)
10/2021
1Tertiary Lymphoid Structures
01/2019
1Liver Diseases (Liver Disease)
01/2019
1Fibrosis (Cirrhosis)
01/2019
1Hepatoblastoma
01/2019
1Leukemia
11/2017
1Infections
06/2008
1Genetic Predisposition to Disease (Genetic Predisposition)
01/2008
1Obesity
01/2008
1Inflammation (Inflammations)
05/2007
1Mason-Type Diabetes
03/2005
1Autosomal Recessive Polycystic Kidney (Polycystic Kidney Disease, Infantile, Type I)
03/2005
1Sarcoma (Soft Tissue Sarcoma)
03/2005
1Type 2 Diabetes Mellitus (MODY)
03/2005
1Renal Cell Carcinoma (Grawitz Tumor)
03/2005
1Endometrial Neoplasms (Endometrial Cancer)
09/2004
1Breast Neoplasms (Breast Cancer)
09/2004

Drug/Important Bio-Agent (IBA)

10beta CateninIBA
01/2020 - 08/2004
5Telomerase (Telomerase Reverse Transcriptase)IBA
05/2022 - 03/2005
5Proteins (Proteins, Gene)FDA Link
01/2020 - 01/2009
5CateninsIBA
01/2019 - 02/2013
5Hepatocyte Nuclear Factor 1-alpha (Hepatocyte Nuclear Factor 1 alpha)IBA
02/2010 - 09/2004
4Transcription Factors (Transcription Factor)IBA
02/2010 - 09/2004
3Messenger RNA (mRNA)IBA
08/2020 - 03/2005
3Biomarkers (Surrogate Marker)IBA
01/2020 - 07/2012
3Oral ContraceptivesIBA
10/2011 - 09/2004
2Cisplatin (Platino)FDA LinkGeneric
10/2021 - 01/2019
2RNA (Ribonucleic Acid)IBA
01/2021 - 01/2019
2Hormones (Hormone)IBA
08/2020 - 09/2004
2Interleukin-6 (Interleukin 6)IBA
01/2020 - 01/2009
2DNA (Deoxyribonucleic Acid)IBA
01/2019 - 01/2007
2Phosphotransferases (Kinase)IBA
01/2019 - 11/2017
2Glutamine (L-Glutamine)FDA Link
01/2019 - 12/2016
2Phenobarbital (Luminal)FDA Link
01/2019 - 11/2014
2Hepatocyte Nuclear FactorsIBA
01/2017 - 03/2005
2RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
12/2016 - 06/2008
2ErbB Receptors (EGF Receptor)IBA
10/2015 - 07/2014
2Fatty Acids (Saturated Fatty Acids)IBA
02/2013 - 05/2007
1Biological ProductsIBA
01/2021
1Antisense OligonucleotidesIBA
01/2021
1Estrogens (Estrogen)FDA Link
08/2020
1AlbuminsIBA
01/2020
1ApolipoproteinsIBA
01/2020
1Apolipoproteins B (ApoB)IBA
01/2020
1Janus KinasesIBA
01/2020
1cabozantinibIBA
01/2019
1Sorafenib (BAY 43-9006)FDA Link
01/2019
1Mechanistic Target of Rapamycin Complex 1IBA
01/2019
1Histone MethyltransferasesIBA
01/2019
1Histones (Histone)IBA
01/2019
1MethyltransferasesIBA
01/2019
1Argininosuccinate Synthase (Argininosuccinate Synthetase)IBA
01/2018
1Ribosomal Protein S6 Kinases (S6 Kinase)IBA
11/2017
1Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
11/2017
1Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
11/2017
1Pharmaceutical PreparationsIBA
11/2017
1tyrosine receptor (receptor, tyrosine)IBA
11/2017
1CDC2 Protein Kinase (Protein p34cdc2)IBA
11/2017
1Vinblastine (Vinblastine Sulfate)FDA Link
08/2017
1JNJ38877605IBA
08/2017
15- ((2,6- dichlorobenzyl)sulfonyl)- 3- ((3,5- dimethyl- 4- ((2- (pyrrolidin- 1- ylmethyl)pyrrolidin- 1- yl)carbonyl)- 1H- pyrrol- 2- yl)methylene)- 1,3- dihydro- 2H- indol- 2- oneIBA
08/2017
1Paclitaxel (Taxol)FDA LinkGeneric
08/2017
1ARQ 197IBA
08/2017
1Aflatoxin B1 (Aflatoxin B)IBA
05/2015
1Cyclin-Dependent Kinase Inhibitor p16IBA
07/2012
1Small Interfering RNA (siRNA)IBA
10/2011
1Estradiol (Delestrogen)FDA LinkGeneric
02/2010
1LigandsIBA
01/2009
1STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA
01/2009
1MicroRNAs (MicroRNA)IBA
06/2008
1Hepatocyte Nuclear Factor 1IBA
05/2007
1Carrier Proteins (Binding Protein)IBA
05/2007
1LipidsIBA
05/2007
1CarbohydratesIBA
05/2007
1Cadherins (E-Cadherin)IBA
01/2007
1UromodulinIBA
03/2005

Therapy/Procedure

5Therapeutics
01/2020 - 01/2007
2Drug Therapy (Chemotherapy)
10/2021 - 01/2019
2Contraception (Birth Control)
02/2013 - 01/2008
1Neoadjuvant Therapy
01/2019